Semaglutide: tablets and new safety information

What did the tablet study show?

OASIS 4 involved 307 adults with obesity or overweight and an additional health problem, without diabetes. People taking semaglutide tablets also received support for lifestyle changes. After 64 weeks, they had lost an average of about 14% of their body weight. [22]

Digestive symptoms were reported by about 74 in 100 people receiving semaglutide. A tablet therefore does not remove the risk of adverse effects. [22]

What is authorised in Europe?

According to current EMA information, Wegovy is now available as an injection pen and tablets. The tablets are intended for adults. This reflects current EU documentation, not a guarantee that every product is available in a Polish pharmacy. [15]

Rybelsus also contains semaglutide in tablet form, but its approved use is type 2 diabetes. Sharing an ingredient name does not mean products can be swapped without guidance. [18]

Why was there a safety update about eyesight?

In June 2025, the EMA recognised NAION, a particular type of optic nerve damage, as a very rare side effect of semaglutide. Very rare means that it may affect up to one in 10,000 users. [23]

For readers, the key warning sign is sudden loss or rapid deterioration of vision. This requires urgent medical contact. It is not a reason to wait until the next scheduled appointment. [23]

What does this mean for a patient?

The question is not only tablet or injection. The indication, effectiveness, tolerance and other conditions matter. The new data do not show that one form will be best for everyone.

You can find the basics, earlier research findings and risks in separate semaglutide profile.

We used current EMA pages, selected document sections and the OASIS 4 study summary. We did not read the full article. The source-check date does not imply automatic monitoring of subsequent changes.

Where does this information come from?